Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001104659-17-006973
Filing Date
2017-02-07
Accepted
2017-02-07 16:02:51
Documents
6
Period of Report
2016-11-29
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A a17-3137_18ka.htm 8-K/A 31080
2 EX-23.1 a17-3137_1ex23d1.htm EX-23.1 2869
3 EX-99.1 a17-3137_1ex99d1.htm EX-99.1 696681
4 EX-99.2 a17-3137_1ex99d2.htm EX-99.2 177739
5 EX-99.3 a17-3137_1ex99d3.htm EX-99.3 305078
6 GRAPHIC g31371mm01i001.jpg GRAPHIC 2120
  Complete submission text file 0001104659-17-006973.txt   1217867
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 000-15006 | Film No.: 17579008
SIC: 2835 In Vitro & In Vivo Diagnostic Substances